$ZyVersa Therapeutics (ZVSA.US)$ ZyVersa Therapeutics强调发布的数据显示,肥胖导致神经炎症,可能涉及神经退行性疾病的发展 ZyVersa Therapeutics (Nasdaq: ZVSA) highlights data published in Aging Celldemonstrating that obesity leads to brain inflammation, potentially increasing the risk of neurodegenerative diseases. The study, conducted on a diet-induced obesity mouse model, showed that: 1. Obesity resulted in significant wei...
ZyVersa Therapeutics股票讨论区
ZyVersa Therapeutics强调评论文章支持除了减肥药概念之外,需要药物治疗肥胖引起的炎症
ZyVersa Therapeutics强调一篇评论文章,支持需要药物治疗肥胖相关炎症以及减肥药物。这篇文章发表在《Life》杂志上,分析了345篇关于炎症小体诱导引起肥胖及其合并症的出版物。肥胖的慢性炎症增加了代谢性疾病、动脉粥样硬化、肿瘤和免疫紊乱的风险。
Zyversa Therapeutics强调已发表的数据显示肥胖导致神经炎症,与神经退行性疾病的发展有关
ZyVersa Therapeutics强调发布的数据显示,肥胖导致神经炎症,可能涉及神经退行性疾病的发展
ZyVersa Therapeutics (Nasdaq: ZVSA) highlights data published in Aging Celldemonstrating that obesity leads to brain inflammation, potentially increasing the risk of neurodegenerative diseases. The study, conducted on a diet-induced obesity mouse model, showed that:
1. Obesity resulted in significant wei...
ZyVersa Therapeutics首席执行官Stephen C. Glover致股东的信中强调,在接下来的九个月内,肥胖发展计划将重点关注Inflammasome ASC 抑制剂 IC 100
ZyVersa Therapeutics(纳斯达克:ZVSA)宣布肥胖伴代谢并发症为其Inflammasome ASC Inhibitor IC 100的主要适应症。公司首席执行官史蒂芬·C·格洛强调了未来九个月内的发展计划和重要里程碑,并在一封致股东的信中详细介绍。预计IC 100将控制肥胖的慢性全身性炎症,减弱相关代谢并发症,并在GLP-1激动剂治疗中加入时促进减重。
明天早上注意这个。100万股,成交量一直在增加。希望它能像TNON一样。
暂无评论